Relato de experiência de um grupo lúdico terapêutico de crianças com incongruência de gênero / An experience report of a ludic therapeutic group of children with gender incongruence

Relato sobre proposta inovadora, que se sustenta como ato terapêutico, lúdico e sequencial, objetivando encontros específicos para trabalhar de maneira psicoterápica questões ligadas às vidas e identidades, inclusive de gênero, dessas crianças. Em 2019, os pacientes de até 12 anos do Ambulatório Transdisciplinar de Identidade de Gênero e Orientação Sexual (AMTIGOS) do IPq/HC/FM/USP foram convidados a participar do Grupo de brincar. O grupo foi acompanhado por uma equipe transdisciplinar e mediado por psicólogos que apresentaram atividades estruturadas de forma a favorecer a explosão por parte das crianças e compartilhamento de suas experiências de forma lúdica.

Longitudinal study of Cystatin C in healthy term newborns.

OBJECTIVE: The purpose of this study was to determine the levels of Cystatin C in healthy term newborns in the first month of life. INTRODUCTION: Cystatin C may be a suitable marker for determining the glomerular filtration rate because it is not affected by maternal renal function. METHODS: Cohort study. Inclusion: term newborns with appropriate weight; mother without renal failure or drugs that could affect fetal glomerular filtration rate. Exclusion: malformations; hypertension or any condition that could affect glomerular filtration rate. Cystatin C (mg/L)and creatinine (rng/dl) were determined in the mother (Mo) and in the newborn at birth (Day-0), 3rd (Day-3), 7th(Day-7) and 28t>h(Day-28) days. STATISTICS: one way ANOVA and Pearson's correlation tests. Sample size of 20 subjects for a = 5% and a power test = 80% (p<0.05). RESULTS: Data from 21 newborns were obtained (mean + standard deviation): MoCystatin C=1.00 ± 0.20; Day-0 Cystatin C 1.70 ± 0.26; Day-3 Cystatin C = 1.51 ± 0.20; Day-7 Cystatin C = 1.54 ± 0.10; Day-28 Cystatin C = 1.51 ± 0.10. MoCystatin C was smaller than Day-0 Cystatin C (p < 0.001), while MoCreatinine was not different from Day-0 Creatinine. Cystatin C only decreased from Day-0 to Day-3 (p = 0.004) but newborns Creatinine decreased along the time. Correlations were obtained between MoCystatin C and MoCreatinine (p = 0.012), as well as Day-3 (p = 0.047) and Day-28 (p = 0.022) Cystatin C and Creatinine values. CONCLUSION: Neonatal Cystatin C values were not affected by MoCystatin C and became stable from the 3rd day of life.

Longitudinal study of Cystatin C in healthy term newborns

OBJECTIVE: The purpose of this study was to determine the levels of Cystatin C in healthy term newborns in the first month of life. INTRODUCTION: Cystatin C may be a suitable marker for determining the glomerular filtration rate because it is not affected by maternal renal function. METHODS: Cohort study. Inclusion: term newborns with appropriate weight; mother without renal failure or drugs that could affect fetal glomerular filtration rate. Exclusion: malformations; hypertension or any condition that could affect glomerular filtration rate. Cystatin C (mg/L)and creatinine (rng/dl) were determined in the mother (Mo) and in the newborn at birth (Day-0), 3rd (Day-3), 7th(Day-7) and 28t>h(Day-28) days. Statistics: one way ANOVA and Pearson's correlation tests. Sample size of 20 subjects for a = 5 percent and a power test = 80 percent (p<0.05). RESULTS: Data from 21 newborns were obtained (mean + standard deviation): MoCystatin C=1.00 ± 0.20; Day-0 Cystatin C 1.70 ± 0.26; Day-3 Cystatin C = 1.51±0.20; Day-7 Cystatin C = 1.54 ± 0.10; Day-28 Cystatin C= 1.51±0.10. MoCystatin C was smaller than Day-0 Cystatin C (p<0.001), while MoCreatinine was not different from Day-0 Creatinine. Cystatin C only decreased from Day-0 to Day-3 (p = 0.004) but newborns Creatinine decreased along the time. Correlations were obtained between MoCystatin C and MoCreatinine (p = 0.012), as well as Day-3 (p = 0.047) and Day-28 (p = 0.022) Cystatin C and Creatinine values. CONCLUSION: Neonatal Cystatin C values were not affected by MoCystatin C and became stable from the 3rd day of life.